Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Targacept (TRGT) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (35)	10/19/2009 7:40:52 AM
From: kenhott	Respond to of 40

The new data set showed the HAMD improvement in real numbers vs. the prior news release which didn't. TC-5214 is the + enantiomer of mecamylamine hydrochloride which they tested in a small phase 2 prior to doing this phase 2 for TC-5214. Inversine (mecamylamine HCL), an old drug, was indicated for hypertension but is no longer marketed by TRGT. Here is the PI: targacept.com Here is the old 2006 phase 2 data release: targacept.com The just completed phase 2, what I can see is pretty strong. One issue is real market protection. Another is that most of the trials were done in India (The earlier phase 2 was also done mostly in India). Another is safety profile. I don't have anything more than the PRs. So I don't know if they broke out more on US/India or safety. I sold my position with the release of the presented data Friday because I had become interested in the stock when they were priced for peanuts and I didn't want to be greedy, also risk was minimal before and is much higher now because of the much higher price. I didn't have a high opinion about TRGT in the past but I thought the phase 2 data in 06 was very interesting.